Ensign Peak Advisors
DNTH icon

Ensign Peak Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Ensign Peak Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Sell
174,187
-30,149
-15% -$2.63M 0.03% 348
2026
Q1 		$17.1M Buy
204,336
+69,920
+52% +$4.05M 0.03% 323
2025
Q4 		$5.54M Hold
134,416
– – 0.01% 503
2025
Q3 		$5.29M Hold
134,416
– – 0.01% 580
2025
Q2 		$2.5M Buy
+134,416
New +$2.52M ﹤0.01% 829
2021
Q2 		– Sell
-198
Closed -$37K – 1838
2021
Q1 		$37K Buy
+198
New +$33.3K ﹤0.01% 1814
2020
Q3 		– Sell
-792
Closed -$95K – 1749
2020
Q2 		$95K Sell
792
-4,127
-84% -$581K ﹤0.01% 1632
2020
Q1 		$495K Sell
4,919
-1,592
-24% -$295K ﹤0.01% 1400
2019
Q4 		$1.58M Buy
+6,511
New +$1.22M ﹤0.01% 1161

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Ensign Peak Advisors's DNTH Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Dianthus Therapeutics (DNTH) stake by 15% in Q2 2026, selling an estimated $2.63M and leaving 174,187 shares worth $17M. The position accounts for 0.03% of the portfolio, ranked #348.

Ensign Peak Advisors first reported a position in DNTH in Q4 2019 and has held it in 9 quarters since. The position peaked at $17.1M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Ensign Peak Advisors held 174,187 shares of Dianthus Therapeutics worth $17M as of Q2 2026.
  • Ensign Peak Advisors sold 30,149 Dianthus Therapeutics shares in Q2 2026, an estimated $2.63M.
  • Dianthus Therapeutics made up 0.03% of Ensign Peak Advisors's portfolio in Q2 2026, its #348 holding.
  • Ensign Peak Advisors first reported a position in Dianthus Therapeutics in Q4 2019 and has held it in 9 quarters since.
  • Ensign Peak Advisors's Dianthus Therapeutics position peaked at $17.1M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.